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Invasive infection caused by carbapenem-resistant Enterobacteria ceae 
(CRE), first documented in the late 1990s, has become a serious global 
public health problem.[1] Resistance to carbapenems may result from 
several mechanisms, including alteration of outer membrane permeability 
due to loss of porins, upregulation of efflux systems together with 
extended-spectrum β-lactamases (ESBLs), or commonly the production 
of carbapenemases.[2] A large number of carbapenemases belonging to 
all four classes of β-lactamases have been described. However, clinically 
relevant carbapenemases belong to three of these classes, namely class 
A β-lactamases such as Klebsiella pneumoniae carbapenemase (KPC) 
and Guiana extended-spectrum carbapenemase (GES), class B metallo-
β-lactamases such as Verona integron-mediated metallo-β-lactamase 
(VIM), imipenemase (IMP) and New Delhi metallo-β-lactamase (NDM), 
and class D β-lactamases including oxacillinase (OXA) subtypes such as 
OXA-48.[3,4] The first CRE invasive infections in South Africa (SA) were 
reported in adult patients from Gauteng Province in 2011, caused by 
NDM-1- and KPC-2-expressing K. pneumoniae isolates.[5] Since then, 
invasive infections caused by CRE-carrying resistance genes of these three 
classes of β-lactamases have been reported in SA.[6]
Publications from the USA, Europe, Asia and the Middle East have 
begun to describe CRE infection in children.[7-15] Age at presentation 
ranged from 0 to 18 years, and ~40% (32/79) were <12 months of age. 
The main types of infection were bloodstream infection, urinary tract 
infection and soft-tissue infection.[7-15] The crude case fatality rate was 
7.4% (5/68).[13-15] A wide spectrum of potential risk factors for CRE 
infection was identified, including previous admission to an intensive care 
unit (ICU), hospitalisation for >48 hours, the presence of an indwelling 
device, underlying medical conditions, necrotising enterocolitis and/or 
short-bowel syndrome, solid organ or stem cell transplantation, exposure 
to immunosuppressants, previous exposure to antibiotics, including 
third-generation cephalosporins, fluoroquinolones or carbapenems, and 
previous infection by a multidrug-resistant organism.[13,15] None of these 
reports was from Africa.
Objectives
To describe a series of cases of CRE at a paediatric hospital and 
document the clinical and microbiological experience of children 
with invasive CRE infection in an SA context.
Methods
A retrospective study was completed at Red Cross War Memorial 
Children’s Hospital (RCWMCH), a tertiary referral hospital in Cape Town 
that cares for sick children. Microbiology specimens from children treated 
at RCWMCH are processed at the central National Health Laboratory 
Service (NHLS) laboratory at Groote Schuur Hospital (GSH), Cape Town. 
The NHLS microbiology database at GSH was searched for minimum 
inhibitory concentration (MIC) breakpoints confirming the presence 
of phenotypic carbapenem resistance of Enterobacteriaceae isolates in 
patients hospitalised at RCWMCH during the period January 2010 - 
December 2015. The Clinical Laboratory Standards Institute (CLSI) MIC 
breakpoints used to establish carbapenem susceptibility or resistance in 
Enterobacteriaceae isolates are summarised in the next section.[16]
Microbiological evaluation
All testing was completed at the NHLS microbiology laboratory, 
GSH. Identification and susceptibility testing of Enterobacteriaceae 
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was carried out primarily with the Vitek 2 system (bioMèrieux, 
France) using the GN and N133 cards, respectively, supplemented 
where necessary with E-test (bioMérieux) to confirm the MICs of 
ertapenem, imipenem and meropenem.
The susceptibility of bacterial isolates was evaluated for the following 
antibiotics: ampicillin, amoxicillin plus clavulanic acid, piperacillin-
tazobactam, cefuroxime, cefoxitin, ceftriaxone, ceftazidime, cefepime, 
ertapenem, meropenem, imipenem, ciprofloxacin, gentamicin, ami-
kacin, co-trimoxazole, tigecycline and colistin.
Carbapenem susceptibility tests were conducted and interpreted 
according to the CLSI 2010 - 2015 criteria.[16] MIC breakpoints for 
Enterobacteriaceae were ≤1 µg/mL (imipenem and meropenem) and 
≤0.5 µg/mL (ertapenem) for susceptible isolates, 2 µg/mL (imipenem 
and meropenem) and 1 µg/mL (ertapenem) for intermediately 
resistant isolates, and ≥4 µg/mL (imipenem and meropenem) and 
≥2 µg/mL (ertapenem) for resistant isolates.
Detection of specific carbapenemase genes was carried out by 
the Centre for Opportunistic, Tropical and Hospital Infections of 
the National Institute of Communicable Diseases, using in-house 
polymerase chain reaction assays. DNA was extracted from cultured 
isolates using the ZR-96 Fungal/Bacterial DNAkit (Zymo Research, 
Inqaba, SA). The following carbapenemase genes were targeted: blaNDM, 
blaVIM, blaIMP, blaKPC, blaGES and blaOXA-48-like.
Case definitions
Invasive CRE infection was diagnosed when CRE was isolated from 
any given body site (other than rectal/faecal swab culture) that was 
associated with clinical manifestations of infection. Hospital-acquired 
infection was defined as CRE infection detected ≥48 hours after 
hospital admission and not incubating at the time of hospitalisation. 
Healthcare-associated infection was defined as CRE infection detected 
within 48 hours of hospitalisation in children who had contact with 
the healthcare service, including admission to an intermediate-care 
facility within the previous 12 months. Community-acquired infection 
was defined as CRE infection detected within 48 hours of hospital 
admission without previous contact with the healthcare service.[17]
Data collection
Clinical information was extracted from the hospital records of 
children with infection caused by CRE, including age, gender, clinical 
manifestations at the time of the CRE culture result, HIV status, and 
antibiotic use during the 12-month period preceding CRE infection, 
antibiotic treatment of the CRE infection and outcome of the CRE 
infection. Microbiological information on the CRE isolates cultured from 
children infected or colonised with CRE was extracted from the NHLS 
microbiology database and included genus and species, results of selective 
carbapenemase gene screening and the antibiotic sensitivity pattern. All 
data were entered on standardised datasheets.
Data analysis
Data were transferred anonymously to an Excel 2010 spreadsheet 
(Microsoft, USA) and analysed using descriptive statistical methods.
Ethical considerations
The study was approved by the Human Research Ethics Committee, 
Faculty of Health Sciences, University of Cape Town (reference 
number: HREC/REF 909/2014), and was conducted in accordance 
with the Declaration of Helsinki.
Results
The first invasive CRE infection at RCWMCH was recorded in November 
2012. A further 9 children developed invasive infection caused by CRE 
during the study period, 1 in 2013, 3 in 2014 and 5 in 2015.
Clinical features of CRE infections
The 10 cases in this series are described in detail in Table 1. The 
median age was 25 months (interquartile range (IQR) 5 - 60). All 
10 children were hospitalised for >48 hours before the onset of their 
CRE infection, implying that all 10 CRE infections were hospital 
acquired. The median length of hospitalisation before CRE infection 
was 28.5 days (IQR 20 - 44). Six of the children developed bloodstream 
infection, 2 manifested with intra-abdominal sepsis, 1 had sepsis and 
empyema and 1 had deep-seated burn wound infection (Table 1). Four 
of the 10 children developed CRE infection in the paediatric ICU. 
Table 2 summarises potential factors contributing to CRE infection.
Five children with CRE infection were treated with parenteral 
colistin (colistimethate sodium, Sanofi), hereafter referred to as 
colistin) and imipenem combination therapy, and 1 child with colistin 
and meropenem combination therapy. Of these 6 patients, 1 died of 
a non-CRE event and one from CRE infection. The remaining 
4 children were treated with colistin monotherapy. All died, 2 from 
CRE infection (patients 3 and 5) and 2 from non-CRE events after 
treatment with colistin monotherapy (patients 8 and 9) (Table 1). 
According to the susceptibility profiles of the pathogens causing 
invasive CRE infection in these patients (Table 3), 1 might have 
benefited from colistin-carbapenem combination therapy (patient 5), 
and 2 from colistin-amikacin combination therapy (patients 3 and 8).
Microbiological characterisation of CRE isolates
Nine CRE infections were caused by K. pneumoniae, while the 
infection in patient 2 was caused by both K. pneumoniae and 
Escherichia coli (Table 3). Carbapenamase genes were identified 
in isolates from 4 of the 8 patients screened. Three and 5 of the 
11  isolates were sensitive to meropenem and imipenem, respec-
tively. None of the isolates was sensitive to ertapenem. Furthermore, 
6/11 (54.5%) and 7/11 (63.6%) of the isolates had MICs ≤4 μg/mL 
for meropenem and imipenem, respectively. All 11 isolates were 
susceptible to colistin and 5 were sensitive to amikacin.
CRE gastrointestinal colonisation
Between 18 May and 29 July 2013, 48 children who had been 
treated in the ward where patient 2 manifested with CRE were 
screened for CRE colonisation by rectal swab culture. Faecal 
colonisation with CRE isolates carrying the NDM gene was 
documented in 4/48 (8.3%). One was colonised by a K. oxytoca 
isolate, 1 by a K. pneumoniae isolate and 2 by E. coli isolates. Of the 
remaining 44 children, 1 was colonised by a carbapenem-resistant 
K. pneumoniae isolate carrying a GES gene, and another by a 
carbapenem-resistant E. coli isolate. This E. coli isolate was Hodge 
test-positive, suggesting that it produced a carbapenemase, but 
none of the six common carbapenemase genes was detected.
Discussion
This is one of the very first studies to report on the outcome of invasive 
CRE infection among children in an African setting. Since the first 
invasive CRE infection was diagnosed at our hospital in November 
2012, there has been a steady increase in the annual number of cases. 
The emergence of CRE infection to some extent follows a change in 
the empirical antibiotic policy for hospital-acquired sepsis. At the 
beginning of 2012, because of escalating numbers of hospital-acquired 
infections caused by ESBL-producing Enterobacteriaceae, empirical 
antibiotic cover for hospital-acquired infections was changed from 
piperacillin-tazobactam plus amikacin to a carbapenem, usually 
ertapenem or, where appropriate, meropenem.[18,19] High carbapenem 
exposure during the 12-month period before the development of 
CRE infection in the 10 patients, together with a general increase in 
carbapenem use at our hospital over time (data not shown), probably 
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Table 2. Potential factors contributing to CRE infection (N=10)
Factor n (%) 
Corresponding cases 
as shown in Table 1
Transfer in from another hospital 2 (20) 1, 10
Colonisation with CRE within 6 months of invasive CRE infection 3 (30) 2, 6, 10
HIV infection 1 (10) 10
Parenteral nutrition at the time of CRE infection 2 (20) 1, 2
Exposure to carbapenems during the preceding 12 months 8 (80) 1, 2, 3, 4, 5, 8, 9, 10
Exposure to cephalosporins during the preceding 12 months 5 (50) 2, 3, 4, 5, 6
Exposure to fluoroquinolones during the preceding 12 months 5 (50) 3, 4, 5, 6, 9
Age <1 year 4 (40) 2, 3, 4, 10
ICU admission within the month preceding CRE infection 8 (80) 1, 2, 3, 5, 6, 7, 9, 10
Surgical procedures/operations within the month preceding CRE infection 6 (60) 1, 2, 4, 6, 7, 8
Central intravenous catheterisation within the month preceding CRE infection 4 (40) 2, 3, 5, 6
Hospitalisation for a period of >14 days within the 6 months preceding CRE infection 8 (80) 1, 2, 3, 5, 7, 8, 9, 10
Two or more hospital admissions within the 12 months preceding CRE infection 3 (30) 3, 5, 8
Immunosuppressive therapy, including glucocorticosteroid therapy, for ≥3 months at the time of CRE infection 3 (30) 4, 5, 8
Table 3. Microbiological characteristics of CRE isolates
Patient Specimen type
Carbapenem-resistant 
pathogens
Carbapenemase 
gene MICs Antibiotic susceptibility profile
1 Peritoneal swab K. pneumoniae Negative Meropenem: 1 µg/mL
Imipenem: 1 µg/mL
Ertapenem: >8 µg/mL
Meropenem, imipenem, colistin
2 Peritoneal swab E. coli blaNDM Meropenem: 2 µg/mL
Imipenem: 4 µg/mL
Ertapenem: >8 µg/mL
Tigecycline, colistin
2 Peritoneal swab K. pneumoniae blaNDM Meropenem: <1 µg/mL
Imipenem: <1 µg/mL
Ertapenem: 1 µg/mL
Amikacin, imipenem, meropenem, 
tigecycline, colistin
3 Blood culture K. pneumoniae blaGES Meropenem: >32 µg/mL
Imipenem: >32 µg/mL
Ertapenem: >8 µg/mL
Amikacin, colistin
4 Blood culture K. pneumoniae Negative Meropenem: 8 µg/mL
Imipenem: 2 µg/mL
Ertapenem: >8 µg/mL
Ciprofloxacin, tigecycline, colistin
5 Blood culture K. pneumoniae Negative Meropenem: 4 µg/mL
Imipenem: 1 µg/mL
Ertapenem: >8 µg/mL
Imipenem, tigecycline, colistin
6 Blood culture K. pneumoniae blaNDM Meropenem: >16 µg/mL
Imipenem: >16 µg/mL
Ertapenem: >8 µg/mL
Colistin
7 Blood culture K. pneumoniae Negative Meropenem: 2 µg/mL
Imipenem: 0.5 µg/mL
Ertapenem: >8 µg/mL
Amikacin, imipenem, colistin
8 Pleural fluid K. pneumoniae blaNDM Meropenem: > 32 µg/mL
Imipenem: >32 µg/mL
Ertapenem: >8 µg/mL
Amikacin, colistin
9 Burn tissue 
swab
K. pneumoniae Not done Meropenem: >16 µg/mL
Imipenem: >32 µg/mL
Ertapenem: >8 µg/mL
Colistin
10 Blood culture K. pneumoniae Not done Meropenem: 0.5 µg/mL
Imipenem: 0.5 µg/mL
Ertapenem: >8 µg/mL
Ciprofloxacin, amikacin, imipenem, 
meropenem, gentamicin, colistin
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contributed to the emergence of carbapenem-resistant isolates in the 
local microflora. Other contributory factors include exposure to other 
antibiotic classes, particularly cephalosporins and fluoroquinolones, 
prolonged hospitalisation (for ≥4 weeks) before the development of 
CRE infection in 6 of the 10 children, prior faecal colonisation with 
CRE in 3 patients, and suboptimal infection control practice.[20]
Inadequate infection control practice was demonstrated during the 
investigation of contacts of patient 2. Of 48 children who were in 
contact with this patient, 4 were asymptomatically colonised with 
Entero bacteriaceae carrying the same carbapenemase gene as patient  2. 
We cannot be certain that colonisation occurred as a result of direct 
transfer from patient 2. However, it is likely that some were colonised 
through direct transfer, given that CRE is easily transmitted between 
humans if adequate containment measures are not implemented, and 
because these children were managed in close proximity to patient 2. [21] 
Colonisation of multidrug-resistant pathogens, including CRE, may 
persist for lengthy periods. In one study of 51 infants colonised with 
ESBL-producing K. pneumoniae, the median faecal carriage time was 
12.5 months and carriage persisted for up to 24 months.[22] In another 
study, of adults in post-acute facilities, faecal carriage of carbapenem-
resistant K. pneumoniae persisted for >10 months in 30% of colonised 
patients. [23] Persistent carriage is therefore an important reservoir for the 
spread of these organisms. Screening also identified 2 patients in contact 
with patient 2 who were colonised by CRE isolates unrelated to that of 
patient  2, indicating that asymptomatic faecal carriage among hospit-
alised children may be widespread, and may have contributed to the 
emergence of CRE infections at our hospital. Prolonged hospitalisation 
and previous admission to an ICU in most of our patients provided the 
opportunity for acquiring CRE from asymptomatic carriers.
In vitro studies have shown enhanced activity against CRE isolates 
with antibiotic combination therapy.[4] Observational studies have 
documented inconsistent outcomes following mono- or combined 
therapy. In one review of case reports and case series, polymyxin 
monotherapy was associated with higher treatment failure rates than 
combination therapy.[24] However, a systematic review of 20 non-
randomised studies showed a mortality rate of up to 67% among 
patients who received colistin-carbapenem combination therapy; 
among patients treated with monotherapy, the mortality rate was up to 
57% for colistin and up to 80% for tigecycline.[25] Observational studies 
suggest that combination therapy is superior in patients with severe 
infections caused by CRE.[4,26] Despite these inconsistencies, there is 
strong support for using combination therapy when treating invasive 
CRE infection. Various combinations have been used, including 
colistin plus a carbapenem, colistin plus tigecycline, colistin plus 
an aminoglycoside, or colistin plus a carbapenem plus tigecycline. 
When combining colistin with a carbapenem, an additive effect may 
be achieved if the carbapenem MIC is ≤4 μg/mL and possibly if it is 
≤8 μg/mL.[4] Six of the children in the current case series were treated 
with combination therapy comprising colistin plus a carbapenem. In 
5 of these, the MICs of the carbapenem-resistant isolates for imipenem 
and/or meropenem were ≤4 μg/mL. The isolate of the remaining child 
(patient 6) had very high meropenem and imipenem MICs. This child’s 
CRE infection was treated successfully, but she died of a subsequent 
Pseudomonas aeruginosa infection (Table 1). All 4 children who were 
treated with colistin monotherapy died. The antibiotic sensitivity 
profiles of their isolates (Table 3) showed that combination antibiotic 
options existed for 3 of these children. Why combination therapy was 
not prescribed is not clear from their clinical notes.
Six of the 10 children died, 3 from non-CRE-related events after 
the treatment of their CRE infections. The CRE-related mortality 
rate of 30% was higher than the crude mortality reported in recent 
paediatric studies, but lower than the mortality recorded in many 
adult studies.[4,13-15,25] Higher mortality in the present case series may 
be due to the small sample size, severe underlying illness, and the 
administration of colistin monotherapy to 40% of the children.
Conclusions
This study has provided useful insights about the patients who acquire 
CRE infection at our hospital and their response to treatment. Until 
randomised controlled trials define optimal treatment strategies, CRE 
infection manifesting in children with severe underlying disease such 
as those described in our case series must be treated with combination 
antibiotic therapy to optimise outcomes. Attention should be focused on 
improving infection control practice to contain the spread of CRE isolates, 
and intensifying antibiotic stewardship to reduce unnecessary antibiotic 
selection pressure and in so doing restrict the number of CRE infections.
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